The Experts below are selected from a list of 6564 Experts worldwide ranked by ideXlab platform

Mohammed Assen Seid - One of the best experts on this subject based on the ideXlab platform.

  • Normalization of Thyroid Function Tests among thyrotoxicosis patients attending a University Hospital in North-West Ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Background Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. Methods A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Results Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Conclusion Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

  • normalization of Thyroid Function Tests among thyrotoxicosis patients attending a university hospital in north west ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

Eyob Alemayehu Gebreyohannes - One of the best experts on this subject based on the ideXlab platform.

  • Normalization of Thyroid Function Tests among thyrotoxicosis patients attending a University Hospital in North-West Ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Background Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. Methods A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Results Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Conclusion Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

  • normalization of Thyroid Function Tests among thyrotoxicosis patients attending a university hospital in north west ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

John P Walsh - One of the best experts on this subject based on the ideXlab platform.

  • familial dysalbuminemic hyperthyroxinemia as a cause for discordant Thyroid Function Tests
    Journal of the Endocrine Society, 2021
    Co-Authors: Matthew J M Ting, Rui Zhang, Ee Mun Lim, Bryan K Ward, Scott G Wilson, John P Walsh
    Abstract:

    Introduction Discordant Thyroid Function Tests are routinely encountered in clinical practice. Differential diagnoses include acute thyroxine (T4) ingestion, laboratory interference from heterophilic antibodies, Thyroid hormone resistance, Thyroid-stimulating hormone (TSH)-secreting pituitary adenomas, and T4 protein binding abnormalities. The impact of abnormal binding proteins may be less recognized since widespread use of free T4 (FT4) assays compared to older total T4 assays. Case report A 69-year-old female was referred for assessment of discordant Thyroid Function Tests. Biochemistry since July 2015 showed persistently elevated FT4 levels by immunoassay ranging between 25 to 34 pmol/L with normal or slightly decreased TSH ranging between 0.05 to 2.74 mU/L. The patient was clinically euThyroid on 100 mcg daily of levothyroxine for Hashimoto's Thyroiditis. FT4 measured using liquid chromatography-tandem mass spectrometry (LC-MS/MS) was 19.5 pmol/L. Exome sequencing (confirmed by Sanger sequencing) detected a guanine to adenine substitution at residue 725 of the ALB gene previously associated with dysalbuminemic hyperthyroxinemia. The patient's daughter had similar Thyroid Function Tests and the same genetic variant. FT4 results from 3 different automated immunoassays showed the Roche Cobas and Siemens Centaur platforms to be most affected by the variant, and Abbott Architect had the best agreement with LC-MS/MS. Conclusion Familial dysalbuminemic hyperthyroxinemia is a potential cause of discordant Thyroid Function Tests. Clinicians suspecting protein-binding abnormalities may further investigate using reference methods such as LC-MS/MS and equilibrium dialysis if available. The increasing accessibility of exome sequencing offers a cost-effective method of diagnosing genetic variants that cause discordant Thyroid Function Tests.

  • assessment of Thyroid Function during pregnancy first trimester weeks 9 13 reference intervals derived from western australian women
    The Medical Journal of Australia, 2008
    Co-Authors: Rhonda M Gilbert, John P Walsh, Narelle Hadlow, Stephen J Fletcher, Suzanne J Brown, Bronwyn G A Stuckey, Ee Mun Lim
    Abstract:

    Objective: To establish first-trimester-specific reference intervals for Thyroid Function Tests in pregnant Australian women. Design, setting and participants: Serum samples were collected from 2159 pregnant women (9-13 weeks' gestation) attending a private pathology practice for first-trimester screening during October and November 2006. Levels of serum thyrotropin (TSH), free thyroxine (fT 4 ), free triiodothyronine (fT 3 ), Thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb) were measured by chemiluminescent immunoassay (Abbott ARCHITECT analyser). Main outcome measures: Reference intervals based on 2.5th and 97.5th percentiles for TSH, fT 4 and fT 3 , after exclusion of 338 women with positive TPOAb or TgAb Tests; comparison with reference intervals for non-pregnant women (TSH, 0.40-4.0 mU/L; fT 4 , 9-19 pmol/L; fT 3 , 3.0-5.5 pmol/L). Results: Derived reference intervals for Thyroid Function Tests during the first trimester of pregnancy were: TSH, 0.02-2.15 mU/L; fT 4 , 10.4-17.8 pmol/L; and fT 3 , 3.3-5.7 pmol/L. If the non-pregnant TSH reference range was applied to the study participants, 344 women (16.0%) whose serum TSH concentration was within the first-trimester-specific reference range would be misclassified as having subclinical hyperThyroidism, and 98 women (4.5%) with a TSH concentration above the first-trimester-specific upper reference limit would not be identified. Conclusions: The reference interval for TSH during the first trimester of pregnancy differs substantially from that for non-pregnant women, and applying the general laboratory reference range to pregnant women results in misclassification of Thyroid status for 20.5% of women. Australian pathology laboratories should adopt pregnancy-specific reference intervals for Thyroid Function Tests.

Emneteab Mesfin Ayele - One of the best experts on this subject based on the ideXlab platform.

  • Normalization of Thyroid Function Tests among thyrotoxicosis patients attending a University Hospital in North-West Ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Background Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. Methods A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Results Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Conclusion Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

  • normalization of Thyroid Function Tests among thyrotoxicosis patients attending a university hospital in north west ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

Soliana Alemayehu Tesfaye - One of the best experts on this subject based on the ideXlab platform.

  • Normalization of Thyroid Function Tests among thyrotoxicosis patients attending a University Hospital in North-West Ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Background Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. Methods A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Results Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Conclusion Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.

  • normalization of Thyroid Function Tests among thyrotoxicosis patients attending a university hospital in north west ethiopia
    Thyroid Research, 2019
    Co-Authors: Eyob Alemayehu Gebreyohannes, Emneteab Mesfin Ayele, Soliana Alemayehu Tesfaye, Mohammed Assen Seid
    Abstract:

    Thyrotoxicosis is a clinical state that results from inappropriately high Thyroid hormone action in tissues. Although it is one of the common endocrine disorders, there is scarcity of data on the management of thyrotoxicosis in Africa, particularly in Ethiopia. The aim of this study was to investigate treatment outcomes and determinants of treatment outcomes among hyperThyroid patients on antiThyroid drugs attending a teaching hospital in Ethiopia. A retrospective cohort study was conducted on medical records of patients with thyrotoxicosis who had attended the medical inpatient ward and chronic ambulatory clinic of the University of Gondar Comprehensive Specialized Hospital in Ethiopia between June 2013 and April 2018. Descriptive statistics were used to summarize socio-demographic and other baseline information. A cox regression method was used to determine factors associated with normalization of Thyroid Function Tests (TFTs). All statistical Tests were performed using STATA version 14. Data from a total 211 patients were eventually analyzed. The mean age of the patients was 47.25 ± 14.26 years with female majority (94.31%). The most common etiology was toxic multinodular goiter (54.90%). Because methimazole or carbimazole are not easily available locally, all of the patients included in this study were taking propylthiouracil (PTU). Nearly 9 out of 10 patients (90.38%) had symptom resolution within a mean period of 5.37 (± 6.59) months. Sixty-two (29.81%) and 122 (58.65%) patients achieved normalization of TSH and FT4, respectively during the study period. The mean time to normalization of TSH and FT4 was 13 (±13.28) and 11.53 (±13.39) months, respectively. On the other hand, T3 and all three TFTs were normalized only among 79 (38.16%) and 55 (26.32%) patients, respectively. Older age and higher baseline FT4 levels were shown to modestly reduce the chances of achieving normalization of TSH. Though PTU is not the preferred antiThyroid agent in the management of thyrotoxicosis, all patients used PTU for the management of hyperThyroidism. All TFTs were normalized in only less than one-third of the participants. Resolution of symptoms took longer period of time than expected.